| Caprelsa (vandetanib) / Sanofi |
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients |
|
|
| Completed | 2 | 106 | US, Europe, RoW | Vandetanib, ZD6474, ZACTIMA™, FOLFIRI | Genzyme, a Sanofi Company | Colorectal Cancer | 03/08 | 11/09 | | |
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 109 | Europe, RoW | Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid | Genzyme, a Sanofi Company | Colorectal, Cancer | 03/08 | 11/16 | | |
NCT00508001: Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) |
|
|
| Completed | 2 | 67 | RoW | Vandetanib, Zactima, ZD6474, Best Supportive Care | Genzyme, a Sanofi Company | Carcinoma, Hepatocellular | 11/08 | 06/09 | | |
|
NCT00445549: Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
|
|
| Terminated | 2 | 12 | US | Vandetanib, Zactima, ZD6474 | National Cancer Institute (NCI) | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms | 12/08 | 10/09 | | |
NCT00683787: Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer |
|
|
| Terminated | 2 | 8 | US | docetaxel, vandetanib | Roswell Park Cancer Institute | Gastric Cancer | 04/09 | 03/11 | | |
| Completed | 2 | 174 | Europe | ZD6474, Vandetanib, Zactima, Gemcitabine, Gemzar, Placebo matching ZD6474 | Genzyme, a Sanofi Company | Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma | 09/12 | 09/12 | | |
NCT00872989: S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
|
|
| Completed | 2 | 129 | US | docetaxel, vandetanib | Southwest Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | 10/13 | 05/14 | | |
|
|
NCT00732745: Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction |
|
|
| Terminated | 1/2 | 9 | US | docetaxel, oxaliplatin, vandetanib, placebo | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | 06/10 | | | |
|
